Specifics on Active & Closed Studies

Alzheimer's Disease Neuroimaging Initiative (ADNI)

Study Status: 
Closed
Study Description: 

We are seeking healthy volunteers and patients with MIild Cognitive Impairment or Mild Alzheimer's disease, ages fifty to ninety, who are interested in taking part in a clinical research study to look at the usefulness of brain scans, cognitive tests and biomarkers to identify early stages of Alzheimer's disease. 

 

Subjects must have a study partner and be willing to come to six to eight visits over the course of two to three years. At each of these visits, subjects will be asked to have blood drawn, undergo tests of memory and have an MRI scan of the brain.  All information is kept completely confidential.

Detecting Early Cognitive Decline in Community-Dwelling Elders

Study Status: 
Closed
Study Description: 

We are seeking adults, sixty-five years of age or order, with at least four years of education, from a variety of ethnic backgrounds to participate in a research study. The purpose of the study is to develop simple methods for understanding memory changes with age.

 

Participants will be asked questions about their memory and must have a friend or relative who can answer five minutes of questions over the telephone about day-to-day activities.  All evaluations will be free of cost and reimbursement for time and transportation is provided. All information is kept confidential.

 

ELIGIBILITY CRITERIA

 

Inclusion criteria:

1. Sixty-five years of age or older.

2. Speak English.

3. Have a friend or relative who can answer five minutes of questions over the telephone about day-to-day activities.

Study Coordinator(s): 

Meghan Frey, MA

Tel:  617-732-8085

A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Patients with Mild to Moderate Alzheimer's Disease

Study Status: 
Closed
Study Description: 

We are seeking patients with mild to moderate Alzheimer's disease to evaluate the tolerability, safety and effectiveness of a new investigational drug that may be a possible treatment for Alzheimer's disease. Bapinuzemab is an investional drug not currently-approved by the US Food and Drug Administration (FDA).

 

Subjects will be randomly-assigned (i.e., by chance, like the flip of a coin) to receive drug or placebo (contains no active medication).  This drug is given intravenously (i.e., through a vein).  Study participants must be able to have an MRI. Study participants will be reimbursed for parking.  All information is kept completely confidential.

 

ELIGIBILITY CRITERIA

 

Inclusion criteria:

1. Age of equal or greater than fifty years.

2. Diagnosis of mild to moderate Alzheimer's disease.

3. Have been on stable doses of FDA-approved treatments such as Aricept, Razadyne, Exelon and/or Namenda (Memantine) for at least four months.

4. A study partner or caregiver who is willing to come to fifteen clinic visits over the course of one-and-a-half years.

 

Exclusion criteria:

1. Significant neurological disease other than Alzheimer's disease.

2. Clinically-significant and/or un-controlled medical condition.

3. Use of an investigational drug within ninety days prior to the screening visit or during the entire study.

Study Coordinator(s): 

Martha Vander Vliet, RN

Tel:  617-732-8085

A Phase IIA, Multi-Center, Randomized, Third-Party UnBlinded, Adjuvant-Controlled, Multiple-Ascending Dose Safety, Tolerability and Immunogenicity Trial of ACC-001 with QS-21 Adjuvant in Patients with Mild to Moderate Alzheimer's Disease

Study Status: 
Closed
Study Description: 

We are seeking Alzheimer's disease patients to evaluate the safety of a new investigational drug called ACC-001 that may be a possible treatment for Alzheimer's disease. ACC-001 is an investigational drug not currently-approved by the US Food and Drug Administration (FDA).

 

Subjects will be randomly-assigned to receive drug or placebo (contains no active medication).  Subjects must have a study partner or caregiver who is able to come to twenty-four clinic visits over the course of two years. Study participants will be reimbursed for parking.  All information is kept completely confidential.

 

ELIGIBILITY CRITERIA

 

Inclusion criteria:

1. Fifty to eighty-five years of age.

2. Diagnosis of mild to moderate Alzheimer's disease (MMSE 16-26).

3. Have been on stable doses of FDA-approved treatments such as Aricept, Reminyl, Exelon, and/or Namenda (Memantine) for at least sixty days.

 

Exclusion criteria:

1. Significant neurological disease other than Alzheimer's disease.

2. Clinically-significant and/or un-controlled medical condition.

3. USe of an investigational drug within thirty days prior to the screening visit or during the entire study.

4. Previous treatment with immuno-therapy for Alzheimer's disease.

Study Coordinator(s): 

Martha Vander Vleit, RN

Tel:  617-732-8085

Amyloid Deposition in Normal Controls: Impact of Cognitive Reserve

Study Status: 
Closed
Study Description: 

The purpose of the study is to develop ways for understanding memory changes that occur with age.  Participants will be asked questions about their memory and must have a friend or relative who can answer ten minutes of questions over the telephone about day-to-day activities.

 

If you qualify, you will be asked to have three brain scans and follow-up memory testing at 12 & 24 months after the initial visit. All evaluations will be free of cost and reimbursement for time and transportation is provided. All information is kept completely confidential..

 

ELIGIBILITY CRITERIA

 

Inclusion criteria:

1. Seventy-five to ninety years of age.

2. Speak English.

3. Have a friend or relative who can answer five minutes of questions over the telephone about day-to-day activities.

4. Willing to undergo three brain scans.

Study Coordinator(s): 

Caroline A. Sullivan, BA

Tel:  617-643-5200

Syndicate content